These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 3449081)
21. Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26. Minocha A; Long BH Biochem Biophys Res Commun; 1984 Jul; 122(1):165-70. PubMed ID: 6331440 [TBL] [Abstract][Full Text] [Related]
22. Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Glisson B; Gupta R; Smallwood-Kentro S; Ross W Cancer Res; 1986 Apr; 46(4 Pt 2):1934-8. PubMed ID: 3004711 [TBL] [Abstract][Full Text] [Related]
23. The epipodophyllotoxin derivatives VM26 and VP16: experimental and clinical aspects. Dombernowsky P; Hansen HH Eur J Haematol Suppl; 1988; 48():49-57. PubMed ID: 3073960 [No Abstract] [Full Text] [Related]
24. The podophyllotoxin derivatives VP16-213 and VM26. Issell BF Cancer Chemother Pharmacol; 1982; 7(2-3):73-80. PubMed ID: 7044593 [TBL] [Abstract][Full Text] [Related]
25. [Synthesis and antitumor activities of 4-acylthiol-4-deoxy-4'-demethylepipodophyllotoxin analogues]. Wang ZG; Zhuang W; Yin SF; Ma WY; Lee BS; Zhang CN Yao Xue Xue Bao; 1992; 27(5):345-8. PubMed ID: 1442054 [TBL] [Abstract][Full Text] [Related]
26. VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity. Loike JD Cancer Chemother Pharmacol; 1982; 7(2-3):103-11. PubMed ID: 7044591 [TBL] [Abstract][Full Text] [Related]
27. [Antitumor effect of etoposide and its analogs]. Kuramochi H; Okamoto K; Nishikawa K; Nagamine S; Takahashi K Gan To Kagaku Ryoho; 1985 Nov; 12(11):2196-201. PubMed ID: 4062319 [TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives. Duca M; Guianvarc'h D; Meresse P; Bertounesque E; Dauzonne D; Kraus-Berthier L; Thirot S; Léonce S; Pierré A; Pfeiffer B; Renard P; Arimondo PB; Monneret C J Med Chem; 2005 Jan; 48(2):593-603. PubMed ID: 15658872 [TBL] [Abstract][Full Text] [Related]
29. Synthesis and antitumor activity of new glycosides of epipodophyllotoxin, analogues of etoposide, and NK 611. Daley L; Guminski Y; Demerseman P; Kruczynski A; Etiévant C; Imbert T; Hill BT; Monneret C J Med Chem; 1998 Nov; 41(23):4475-85. PubMed ID: 9804687 [TBL] [Abstract][Full Text] [Related]
30. Synthesis and antitumor activity of novel per-butyrylated glycosides of podophyllotoxin and its derivatives. Zi CT; Yang D; Dong FW; Li GT; Li Y; Ding ZT; Zhou J; Jiang ZH; Hu JM Bioorg Med Chem; 2015 Apr; 23(7):1437-46. PubMed ID: 25744190 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological activity of sulfonamide derivatives of epipodophyllotoxin. Guianvarc'h D; Duca M; Boukarim C; Kraus-Berthier L; Léonce S; Pierré A; Pfeiffer B; Renard P; Arimondo PB; Monneret C; Dauzonne D J Med Chem; 2004 Apr; 47(9):2365-74. PubMed ID: 15084135 [TBL] [Abstract][Full Text] [Related]
32. Antitumor agents. Part 227: Studies on novel 4'-O-demethyl-epipodophyllotoxins as antitumor agents targeting topoisomerase II. Xiao Z; Bastow KF; Vance JR; Lee KH Bioorg Med Chem; 2004 Jun; 12(12):3339-44. PubMed ID: 15158802 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. Evans WE; Sinkule JA; Crom WR; Dow L; Look AT; Rivera G Cancer Chemother Pharmacol; 1982; 7(2-3):147-50. PubMed ID: 7083455 [TBL] [Abstract][Full Text] [Related]
34. Comparative study of early effects of epipodophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures. Grieder A; Maurer R; Stähelin H Cancer Res; 1977 Sep; 37(9):2998-3005. PubMed ID: 69488 [No Abstract] [Full Text] [Related]
35. Synthesis and cytotoxic evaluation of C-9 oxidized podophyllotoxin derivatives. Castro MA; Miguel del Corral JM; Gordaliza M; García PA; Gómez-Zurita MA; San Feliciano A Bioorg Med Chem; 2007 Feb; 15(4):1670-8. PubMed ID: 17197187 [TBL] [Abstract][Full Text] [Related]
36. Overexpression of multidrug resistance protein gene in human cancer cell lines selected for drug resistance to epipodophyllotoxins. Koike K; Abe T; Hisano T; Kubo T; Wada M; Kohno K; Kuwano M Jpn J Cancer Res; 1996 Jul; 87(7):765-72. PubMed ID: 8698628 [TBL] [Abstract][Full Text] [Related]
37. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883 [TBL] [Abstract][Full Text] [Related]
38. Sensitization of human glioblastoma T98G cells to VP16 and VM26 by human tumor necrosis factor. Morgavi P; Cimoli G; Ottoboni C; Michelotti A; Conte P; Parodi S; Russo P Anticancer Res; 1995; 15(4):1423-8. PubMed ID: 7654031 [TBL] [Abstract][Full Text] [Related]
39. Podophyllotoxin derivatives VP-16 and VM-26. D'Incalci M; Garattini S Cancer Chemother Biol Response Modif; 1988; 10():57-63. PubMed ID: 3079398 [No Abstract] [Full Text] [Related]
40. Current development of podophyllotoxins. Canetta R; Hilgard P; Florentine S; Bedogni P; Lenaz L Cancer Chemother Pharmacol; 1982; 7(2-3):93-8. PubMed ID: 7044596 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]